Abstract:The p53 gene is the most commonly mutated tumor suppressor gene in human cancers. It has been well established that p53 plays multiple tumor suppression roles in cells upon introduction of stresses: cell cycle G1 and G2 arrest or apoptosis, in part depending on the cell types.1 Structural and functional analyses of p53 have shown that p53 is a transcription factor with a sequence-specific DNA-binding domain in the central region and a transcriptional activation domain at the N-terminal.1 Three additional domains, including a nuclear localization signal, a tetramerization domain and an extreme C-terminal regulatory domain, are present in the C-terminal of p53. The transcriptional activities of p53 are essential for its tumor suppression functions. p21, a downstream target of p53 and a universal inhibitor of cyclin-dependent kinases, plays a major role in mediating p53-dependent cell cycle G1 arrest.2,3,4 While earlier studies reached conflicting conclusions on the requirement of p53 transcriptional activities in p53-dependent apoptosis,1 recent analysis of knockin mice and cells, in which two missense mutations encoding Gln and Ser in place of Leu25 and Trp26 were introduced into the endogenous p53 gene, indicated that p53 transcriptional activities are essential for p53-dependent apoptosis.5,6 Therefore, identification of genes whose expression is either activated or repressed by p53 will be essential in order to understand the mechanism of p53-dependent tumor suppression. In response to DNA damage and other cellular stresses, the protein levels of p53 are greatly upregulated and its activities induced. It had been postulated that p53 was present in an inactive form in normal cells in the absence of stress.1 In this context, the extreme C-terminal of p53 was proposed a role in negatively regulating the sequence-specific DNA binding of p53.7,8,9 However, evidence provided by two recent studies argued against such a model and indicated that p53 could bind to its sequence-specific DNA-binding site in cells in the absence of stress.10,11 Therefore, it remains to be elucidated how p53 activities are induced after introduction of stress. The induction of p53 protein levels post stresses is regulated post-translationally and mainly because of increased protein stability.1 MDM2, a transcriptional target of p53, plays a major role in the regulation of p53 stability.12,13 MDM2 interacts with the N-terminal of p53 and this interaction could inhibit p53 transcriptional activity.14 In addition, MDM2 acts as the E3 ligase for p53 and thus promotes p53 ubiquitination and degradation.15,16,17,18,19 Therefore, MDM2-p53 interaction represents a negative autoregulatory mechanism to regulate p53 stability and activity. Accumulating evidence has indicated that post-translational modifications of p53 and MDM2, including phosphorylation, acetylation and sumoylation, could modulate their interaction and thus p53 stability and activity. Human p53 is phosphorylated at multiple sites at the N- and C-terminal in vitro by a number of kinases, and most of these phosphorylation sites are conserved between human and mouse p53 (Table 1). However, several phosphorylation sites within the proline-rich domain are not conserved between human and mouse p53. For example, Ser46 of human p53 can be phosphorylated by a number of kinases after DNA damage (Figure 1a;20,21,22,23). There is no apparent mouse homolog of human Ser46. Several p53 phosphorylation events have been extensively studied. ATM family kinases are required for the rapid phosphorylation of human p53 at Ser15 following DNA damage (Figure 1a;24,25,26). One study reported that phosphorylation of p53 at Ser15 disrupted its interactions with MDM2, leading to p53 stabilization.27 An additional study suggested that Ser15 phosphorylation might stabilize p53 by preventing p53 nuclear export.28 However, others have presented evidence arguing that Ser15 phosphorylation did not disrupt MDM2–p53 interaction, but was required for p53 acetylation and activation.29,30,31 To address the physiological significance of Ser15 phosphorylation in the p53 responses to DNA damage, a missense mutation was introduced into the endogenous p53 gene in mice that changed the nucleotides encoding Ser18 (corresponding to Ser15 of human p53) to those encoding alanine. Analysis of the homozygous p53Ser18Ala ES cells and differentiated ES cells indicated that phosphorylation of mouse p53 at Ser18 is required for the maximum p53 responses to DNA damage.32 However, in contrast to the previous studies suggesting that phosphorylation of human p53 at Ser15 was required for p53 acetylation after DNA damage, analysis of p53 acetylation in p53Ser18Ala differentiated ES cells indicated that the phosphorylation of p53 at Ser18 was neither necessary nor sufficient to activate p53 acetylation at C-terminal.5,32 One possible explanation for this discrepancy is that the requirement of Ser18 phosphorylation in p53 acetylation is cell-type specific. Analysis of DNA damage-induced p53 acetylation in other cell types derived from p53Ser18Ala mice could test this possibility. Alternatively, it is possible that the mechanism regulating p53 acetylation is different between humans and the mouse. Ser20 of human p53 and corresponding Ser23 of mouse p53 are phosphorylated in vivo following DNA damage.13,33 This phosphorylation event is mediated by Chk2 kinase, which is activated by ATM family kinases after DNA damage (Figure 1a;33,34,35,36). Several studies have suggested that phosphorylation of human p53 at Ser20, which is located within the helix involved in MDM2 interaction, is important for p53 stabilization after DNA damage by disrupting MDM2–p53 interaction.33,34,35 However, several other studies indicated that phosphorylation of human p53 at Ser20 did not affect MDM2-p53 interaction.37,38 To address the physiological significance of phosphorylation of mouse p53 at Ser23 in p53 responses to DNA damage, knockin ES cells, in which the missense Ser23 (corresponding to Ser20 of human p53) to Ala mutation was introduced into the endogenous p53 gene, were generated. Studies of the p53Ser23Ala ES cells, embryonic fibroblasts and thymocytes indicated that phosphorylation of mouse p53 at Ser23 was not required for p53 stabilization after DNA damage.39 It is possible that Ser23 phosphorylation is required for more subtle responses to DNA damage and this will await future analysis of p53Ser23Ala germline knockin mice. This finding suggests that, in the absence of Ser23 phosphorylation, other phosphorylation events of p53 could stabilize p53 to normal levels. Consistent with this notion, phosphorylation of Thr18, which is also located within the region of p53 interacting with MDM2,40 could interrupt p53–MDM2 interaction leading to p53 stabilization. Several possibilities can be considered to explain the discrepancy between this conclusion and the earlier ones, which indicated an important role of Ser20 phosphorylation in the disruption of p53–MDM2 interaction. First, it is possible that phosphorylation of human p53 at Ser20 and mouse p53 at Ser23 have different roles in regulating p53 stability and activity. However, several lines of evidence argued against this possibility. The human p53 knockin mice, in which the core region (amino-acid sequence 33–332) of the endogenous mouse p53 was replaced with the human counterpart, have normal p53 responses to DNA damage and p53-dependent tumor suppression.41 This indicates that the DNA-damaged-induced signaling pathways leading to the activation of p53 responses are highly conserved between human and the mouse. In addition, the amino-acid sequence between 13 and 27 (human numbering) is identical between human and mouse p53. Secondly, most previous assays involved the overexpression of mutant p53 in tumor cell lines. It is possible that tumor cells are defective in certain signaling pathways leading to the phosphorylation of p53 at other sites, contributing to the more apparent requirement of Ser20 phosphorylation in p53 stabilization. A number of other phosphorylation events of mouse and human p53 have been identified after DNA damage or during cellular proliferation. The kinases involved in these phosphorylation events and the potential roles of these phosphorylation events in regulating p53 stability and activity are summarized in Table 1. CREB-binding protein (CBP) and p300 can coactivate numerous transcriptional factors, including p53.30,42,43 Both PCAF and p300 possess intrinsic histone acetyltransferase activity and can acetylate human p53 at Lys320 and Lys372/373/381/382, respectively (Figure 1b;42,44,45). In addition, these lysine residues of p53 are also acetylated in response to DNA damage in vivo.44,45 Several mechanisms have been proposed to account for the regulation of p53 acetylation at C-terminal. DNA damage-induced phosphorylation of p53 might regulate the interaction between PCAF/p300 and p53. In support of this notion, two studies suggested that phosphorylation of p53 at Ser15 or Ser33/37 promotes the interaction between p53 and CBP/p300 (Figure 1b;31,44). Secondly, MDM2, which destabilizes p53 by promoting p53 ubiquitination, might also suppress p300-mediated p53 acetylation by forming a complex with p300 and p53 (Figure 1b;46). Thirdly, tumor suppressor PML could induce p53 acetylation through the formation of a trimeric p53–PML–CBP complex.47 While an earlier study suggested that the acetylation of p53 at C-terminal Lys residues can activate p53 sequence-specific DNA-binding activity in vitro,42 human p53 with mutations at multiple acetylation sites at the C-terminal (Lys372,373,381,382 to Ala) appears to be functional in both sequence-specific DNA-binding and transactivation.48,49 In addition, recent analysis of the DNA-binding activities of a p53 mutant, which harbored multiple Lys to Arg mutations at the acetylation sites, indicated that p53 acetylation by p300 was not required for sequence-specific DNA binding activities of p53.10 However, this study also indicated that the C-terminal of p53 and recruitment of p300 to the p53-dependent promoters were required for p53 transcriptional activities. The involvement of p53 acetylation in activating its transcriptional activities was suggested by the findings that p53 acetylation was required for the recruitment of CBP/p300 to the p53-dependent promoters.50 Another potential role of p53 acetylation is to regulate p53 stability. While MDM2 binds to the N-terminal of p53, the extreme C-terminal region of p53 (362–392) is also required for the efficient MDM2-mediated degradation.15 Several recent studies have managed to identify the elements within the extreme C-terminal of p53 that might be involved in regulating MDM2-mediated p53 degradation. By mutating the six Lys residues (370, 372, 373, 381, 382 and 386) to Arg at the C-terminal, one study showed that these mutations (K6R) essentially abolished the MDM2-mediated ubiquitination of p53, suggesting that these lysine residues are the ubiquitination sites.49 Consistent with this finding, another group mutated four lysine residues 370, 373, 381 and 382) into Ala (K4A) and the K4A mutation also impaired the MDM2-mediated ubiquitination.48 MDM2 bound to K6R and K4A p53 mutants equally well when compared to the wild-type p53, indicating that the defective p53 ubiquitination was not because of the impaired MDM2–p53 interaction. Since the C-terminal lysine residues ubiquitinated by MDM2 are the same residues for acetylation after DNA damage, acetylation of these lysine residues after DNA damage could prevent ubiquitination at the same sites, leading to p53 stabilization. Recent studies have shown that phospho- or acetylation-specific antibodies, which recognize p53 modified at a particular site, are indispensable tools to study the regulation and interaction among various post-translational modification events. Development of a complete set of these antibodies to modified mouse and human p53 in the future will be critical to identify the unique patterns of post-translational modifications induced by a particular stress stimulus and the interactions between the various post-translational modifications. Overexpression of p53 mutants in tumor cell lines is a risky experimental approach and the conclusions from such studies will require verification for their physiological relevance. Studies employing mouse knockin technology could address the physiological roles of p53 post-translational modifications, but will represent a major effort. Some phosphorylation sites within the proline-rich domain of mouse and human p53 are not conserved. The physiological importance of these unconserved phosphorylation events of human p53 could now be tested using the humanized p53 knockin mouse model, in which the core region of human p53 (33–332) has replaced the mouse counterpart.41 However, this requires that the stress-induced signaling pathways leading to these phosphorylation events be conserved between the mouse and human cells. Finally, identification of the phosphorylation events and subsequently the signaling pathways required for p53 activation in response to DNA damage will have important clinical applications, including a screen for defects in these signaling pathways in tumor cells expressing a wild-type but dysfunctional p53. I thank CW Anderson, C Murre and members of my laboratory for critically reading this manuscript. Supported by grants from DOD Breast Cancer Research Program and National Cancer Institute.

Abstract:In response to DNA damage, the activity of the p53 tumor suppressor is modulated by protein stabilization and post-translational modifications including acetylation. Interestingly, both acetylation and ubiquitination can modify the same lysine residues at the C terminus of p53, implicating a role of acetylation in the regulation of p53 stability. However, the direct effect of acetylation on Mdm2-mediated ubiquitination of p53 is still lacking because of technical difficulties. Here, we have developed a method to obtain pure acetylated p53 proteins from cells, and by using an in vitro purified system, we provide the direct evidence that acetylation of the C-terminal domain is sufficient to abrogate its ubiquitination by Mdm2. Importantly, even in the absence of DNA damage, acetylation of the p53 protein is capable of reducing the ubiquitination levels and extending its half-life in vivo. Moreover, we also show that acetylation of p53 can affect its ubiquitination through other mechanisms in addition to the site competition. This study has significant implications regarding a general mechanism by which protein acetylation modulates ubiquitination-dependent proteasome proteolysis. In response to DNA damage, the activity of the p53 tumor suppressor is modulated by protein stabilization and post-translational modifications including acetylation. Interestingly, both acetylation and ubiquitination can modify the same lysine residues at the C terminus of p53, implicating a role of acetylation in the regulation of p53 stability. However, the direct effect of acetylation on Mdm2-mediated ubiquitination of p53 is still lacking because of technical difficulties. Here, we have developed a method to obtain pure acetylated p53 proteins from cells, and by using an in vitro purified system, we provide the direct evidence that acetylation of the C-terminal domain is sufficient to abrogate its ubiquitination by Mdm2. Importantly, even in the absence of DNA damage, acetylation of the p53 protein is capable of reducing the ubiquitination levels and extending its half-life in vivo. Moreover, we also show that acetylation of p53 can affect its ubiquitination through other mechanisms in addition to the site competition. This study has significant implications regarding a general mechanism by which protein acetylation modulates ubiquitination-dependent proteasome proteolysis. CREB-binding protein (where CREB is cAMP-response element-binding protein) histoneacetyl-transferase glutathioneS-transferase dithiothreitol phenylmethylsulfonyl fluoride trichostatin A ubiquitin-activating enzyme ubiquitin carrier protein ubiquitin-protein isopeptide ligase The p53 tumor suppressor exerts antiproliferative effects, including growth arrest, apoptosis, and cell senescence, in response to various types of stress (1Appella E. Anderson C.W. Pathol. Biol. (Paris). 2000; 48: 227-245PubMed Google Scholar, 2Prives C. Manley J.L. Cell. 2001; 107: 815-818Abstract Full Text Full Text PDF PubMed Scopus (189) Google Scholar, 3Ashcroft M. Vousden K.H. Oncogene. 1999; 18: 7637-7643Crossref PubMed Scopus (369) Google Scholar, 4Pearson M. Carbone R. Sebastiani C. Cioce M. Fagioli M. Saito S. Higashimoto Y. Appella E. Minucci S. Pandolfi P.P. Pelicci P.G. Nature. 2000; 406: 207-210Crossref PubMed Scopus (1121) Google Scholar). Inactivation of p53 function appears to be critical to tumorigenesis in all different types of human cancers (5Vogelstein B. Lane D. Levine A.J. Nature. 2000; 408: 307-310Crossref PubMed Scopus (5745) Google Scholar). p53 is a short-lived protein whose activity is maintained at low levels in normal cells (3Ashcroft M. Vousden K.H. Oncogene. 1999; 18: 7637-7643Crossref PubMed Scopus (369) Google Scholar). Tight regulation of p53 is essential for its effect on tumorigenesis as well as maintaining normal cell growth. The precise mechanism by which p53 is activated by cellular stress is not completely understood; it is generally thought to involve mainly post-translational modifications of p53, including ubiquitination, phosphorylation, and acetylation (1Appella E. Anderson C.W. Pathol. Biol. (Paris). 2000; 48: 227-245PubMed Google Scholar, 2Prives C. Manley J.L. Cell. 2001; 107: 815-818Abstract Full Text Full Text PDF PubMed Scopus (189) Google Scholar, 3Ashcroft M. Vousden K.H. Oncogene. 1999; 18: 7637-7643Crossref PubMed Scopus (369) Google Scholar, 4Pearson M. Carbone R. Sebastiani C. Cioce M. Fagioli M. Saito S. Higashimoto Y. Appella E. Minucci S. Pandolfi P.P. Pelicci P.G. Nature. 2000; 406: 207-210Crossref PubMed Scopus (1121) Google Scholar).Early studies demonstrated that CBP1/p300, ahistone acetyl-transferase (HAT), acts as a coactivator of p53 and potentiates its transcriptional activity as well as biological function in vivo; significantly, the observation of functional synergism between p53 and CBP/p300 together with its intrinsic HAT activity led to the discovery of a novel FAT (transcriptional factoracetyl-transferase) activity of CBP/p300 on p53 (5Vogelstein B. Lane D. Levine A.J. Nature. 2000; 408: 307-310Crossref PubMed Scopus (5745) Google Scholar, 6Gu W. Roeder R.G. Cell. 1997; 90: 595-606Abstract Full Text Full Text PDF PubMed Scopus (2152) Google Scholar, 7Kouzarides T. EMBO J. 2000; 19: 1176-1179Crossref PubMed Scopus (998) Google Scholar). p53 is specifically acetylated at multiple lysine residues (Lys-370, Lys-371, Lys-372, Lys-381, Lys-382) of the C-terminal regulatory domain by CBP/p300. The acetylation of p53 can dramatically stimulate its sequence-specific DNA binding activity, possibly as a result of an acetylation-induced conformational change (6Gu W. Roeder R.G. Cell. 1997; 90: 595-606Abstract Full Text Full Text PDF PubMed Scopus (2152) Google Scholar, 7Kouzarides T. EMBO J. 2000; 19: 1176-1179Crossref PubMed Scopus (998) Google Scholar, 8Sterner D.E. Berger S.L. Microbiol. Mol. Biol. Rev. 2000; 64: 435-459Crossref PubMed Scopus (1385) Google Scholar). By developing site-specific acetylated p53 antibodies, CBP/p300-mediated acetylation of p53 was further confirmed in vivo by a number of studies (9Sakaguchi K. Herrera J.E. Saito S. Miki T. Bustin M. Vassilev A. Anderson C.W. Appella E. Genes Dev. 1998; 12: 2831-2841Crossref PubMed Scopus (1013) Google Scholar, 10Liu L. Scolnick D.M. Trievel R.C. Zhang H.B. Marmorstein R. Halazonetis T.D. Berger S.L. Mol. Cell. Biol. 1999; 19: 1202-1209Crossref PubMed Scopus (648) Google Scholar, 11Liu Y. Colosimo A.L. Yang X.J. Liao D. Mol. Cell. Biol. 2000; 20: 5540-5553Crossref PubMed Scopus (80) Google Scholar). In addition, p53 can also be acetylated at Lys-320 by another HAT cofactor, p300/CBP-asssociated factor, although the in vivo functional consequence needs to be further elucidated (9Sakaguchi K. Herrera J.E. Saito S. Miki T. Bustin M. Vassilev A. Anderson C.W. Appella E. Genes Dev. 1998; 12: 2831-2841Crossref PubMed Scopus (1013) Google Scholar, 10Liu L. Scolnick D.M. Trievel R.C. Zhang H.B. Marmorstein R. Halazonetis T.D. Berger S.L. Mol. Cell. Biol. 1999; 19: 1202-1209Crossref PubMed Scopus (648) Google Scholar, 12Ito A. Lai C.H. Zhao X. Saito S. Hamilton M.H. Appella E. Yao T.P. EMBO J. 2001; 20: 1331-1340Crossref PubMed Scopus (436) Google Scholar). Significantly, the steady-state levels of acetylated p53 are stimulated in response to various types of stress, indicating the important role of p53 acetylation in stress response (11Liu Y. Colosimo A.L. Yang X.J. Liao D. Mol. Cell. Biol. 2000; 20: 5540-5553Crossref PubMed Scopus (80) Google Scholar).By serving as a signal for specific cellular protein degradation, ubiquitination plays a critical role in physiological regulation of many cellular processes (13Pickart C.M. Annu. Rev. Biochem. 2001; 70: 503-533Crossref PubMed Scopus (2887) Google Scholar, 14Hershko A. Ciechanover A. Varshavsky A. Nat. Med. 2000; 6: 1073-1081Crossref PubMed Scopus (564) Google Scholar). The ubiquitination of p53 was first discovered in papilloma virus-infected cells through the functions mediated by the viral E6 protein (15Scheffner M. Huibregtse J.M. Vierstra R.D. Howley P.M. Cell. 1993; 75: 495-505Abstract Full Text PDF PubMed Scopus (1952) Google Scholar); however, in normal cells, Mdm2 functions as an ubiquitin ligase and plays a major role in p53 ubiquitination and subsequent degradation (16Haupt Y. Maya R. Kazaz A. Oren M. Nature. 1997; 387: 296-299Crossref PubMed Scopus (3658) Google Scholar, 17Kubbutat M.H. Jones S.N. Vousden K.H. Nature. 1997; 387: 299-303Crossref PubMed Scopus (2813) Google Scholar, 18Honda R. Tanaka H. Yasuda H. FEBS Lett. 1997; 420: 25-27Crossref PubMed Scopus (1587) Google Scholar). Like in the case of acetylation, the ε-amino group of the substrate lysine residue is also the target for ubiquitination (13Pickart C.M. Annu. Rev. Biochem. 2001; 70: 503-533Crossref PubMed Scopus (2887) Google Scholar, 14Hershko A. Ciechanover A. Varshavsky A. Nat. Med. 2000; 6: 1073-1081Crossref PubMed Scopus (564) Google Scholar). Significantly, recent studies have indicated that the lysine residues at the C-terminal domain of p53, five of which are the acetylation sites, play a critical role in Mdm2-mediated ubiquitination and subsequent degradation (19Rodriguez M.S. Desterro J.M. Lain S. Lane D.P. Hay R.T. Mol. Cell. Biol. 2000; 20: 8458-8467Crossref PubMed Scopus (300) Google Scholar, 20Nakamura S. Roth J.A. Mukhopadhyay T. Mol. Cell. Biol. 2000; 20: 9391-9398Crossref PubMed Scopus (160) Google Scholar, 21Gu J. Nie L. Wiederschain D. Yuan Z.M. Mol. Cell. Biol. 2001; 21: 8533-8546Crossref PubMed Scopus (76) Google Scholar, 22Lohrum M.A. Woods D.B. Ludwig R.L. Balint E. Vousden K.H. Mol. Cell. Biol. 2001; 21: 8521-8532Crossref PubMed Scopus (194) Google Scholar). Furthermore, increasing the levels of p53 acetylation with deacetylase inhibitors in the cell also prevents p53 from degradationin vivo (11Liu Y. Colosimo A.L. Yang X.J. Liao D. Mol. Cell. Biol. 2000; 20: 5540-5553Crossref PubMed Scopus (80) Google Scholar). Therefore, it is reasonable to speculate that acetylation of p53 may directly regulate its ubiquitination levelsin vivo. However, thus far, there is no direct evidence regarding how p53 acetylation affects its ubiquitination, mainly because of the technical difficulties. In this study, we have developed several assays to establish an important mechanism that p53 acetylation is directly involved in the regulation of its ubiquitination and subsequent proteolysis induced by Mdm2.RESULTS AND DISCUSSIONOne of the major obstacles in elucidating the precise role of acetylation in the regulation of protein function is obtaining the pure acetylated form. Since the acetylated non-histone proteins are inseparable from the unacetylated forms on the regular SDS-PAGE gel, thus far, most of the functional studies on newly identified acetylated substrates, including p53, are derived from the “acetylated proteins” without any quantitative analysis of their contents (6Gu W. Roeder R.G. Cell. 1997; 90: 595-606Abstract Full Text Full Text PDF PubMed Scopus (2152) Google Scholar, 7Kouzarides T. EMBO J. 2000; 19: 1176-1179Crossref PubMed Scopus (998) Google Scholar, 8Sterner D.E. Berger S.L. Microbiol. Mol. Biol. Rev. 2000; 64: 435-459Crossref PubMed Scopus (1385) Google Scholar, 9Sakaguchi K. Herrera J.E. Saito S. Miki T. Bustin M. Vassilev A. Anderson C.W. Appella E. Genes Dev. 1998; 12: 2831-2841Crossref PubMed Scopus (1013) Google Scholar, 10Liu L. Scolnick D.M. Trievel R.C. Zhang H.B. Marmorstein R. Halazonetis T.D. Berger S.L. Mol. Cell. Biol. 1999; 19: 1202-1209Crossref PubMed Scopus (648) Google Scholar, 11Liu Y. Colosimo A.L. Yang X.J. Liao D. Mol. Cell. Biol. 2000; 20: 5540-5553Crossref PubMed Scopus (80) Google Scholar, 12Ito A. Lai C.H. Zhao X. Saito S. Hamilton M.H. Appella E. Yao T.P. EMBO J. 2001; 20: 1331-1340Crossref PubMed Scopus (436) Google Scholar). Therefore, it is very difficult to provide consistent results about the functional differences between the “unacetylated form” and the “acetylated form” of these proteins as the acetylated form may be heavily contaminated with the unacetylated form. To provide direct evidence that acetylation of p53 can modulate its ubiquitination by Mdm2, we had to obtain the pure form of acetylated p53 from cells. Interestingly, our preliminary data indicated that the acetylated p53 protein reacts poorly to PAb421, one of the p53 antibodies, although it can be recognized perfectly well by several other p53 antibodies including DO-1 (data not shown, also see Fig. 1). Since the PAb421 antibody was raised specifically against the C-terminal domain of p53, overlapping with the sites for acetylation (Fig. 1 a), it is very likely that acetylation of the C-terminal domain may prevent p53 from binding to the PAb421 antibody. This piece of information provided an important clue, that the unacetylated p53 form can be specifically removed from the acetylated p53 fractions through the differential bindings with the PAb421 antibody, for purification of the acetylated p53 form.Thus, we applied a two-step strategy to purify the pure form of acetylated p53 from human cells. First, we purified total p53 proteins from cell extracts, and second, we isolated the acetylated p53 from the total p53 proteins by the PAb421 antibody column (Fig. 1 b). As indicated in Fig. 1 c, the acetylation levels of p53 were enhanced significantly when the FLAG-tagged p53 protein was coexpressed with p300 in H1299 cells (lane 2 versus lane 1), and these transfected cells provided a good resource for the purification of acetylated p53 proteins. By using the M2/FLAG column, the total p53 proteins were purified from these cell extracts, but heavily contaminated with unacetylated p53 proteins (data not shown). Then, we loaded them on the PAb421 antibody column to deplete the unacetylated form of p53 (Fig. 1 b), and the purified acetylated p53 proteins were finally tested for their purities. As shown in Fig. 1 d, the purified acetylated p53 was easily detected by the acetylated p53-specific antibody (lane 2 versus lane 1, upper panel). Both acetylated and unacetylated forms of p53 reacted equally well to the DO-1 antibody (lane 2 versus lane 1, middle panel), which is against the N-terminal domain of p53 (Fig. 1 a). Significantly, the purified acetylated p53 protein could not be detected by the PAb421 antibody at all (lane 2 versus lane 1, lower panel). These data indicate that acetylation of the p53 protein by p300 can block the recognition site for the PAb421 antibody. More importantly, we have obtained the pure form of acetylated p53 from cells without obvious contamination from unacetylated p53 proteins.To provide the direct evidence that acetylation of p53 affects its ubiquitination, we set up a reconstitution system for p53 ubiquitination by Mdm2. As indicated in Fig. 2 a, the E2 (GST-UbcH5c) and E3 (GST-Mdm2) were expressed in bacteria as GST fusion proteins and purified to near homogeneity (lanes 5 and 3), ubiquitin was expressed as a His-tagged protein and obtained by a similar manner (lane 7), and the E1 was purchased as a purified protein (lane 2). The highly purified in vitro system was used in this assay to avoid any possible indirect effect by other factors on p53 ubiquitination. To define the purified system for p53 ubiquitination, we first tested whether all purified components can support Mdm2-dependent ubiquitination of an unmodified form of p53 in vitro. Indeed, as shown in Fig. 2 b, the bacteria-produced p53 protein was specifically ubiquitinated only in the presence of Mdm2 (lane 5). Importantly, as shown in Fig. 2 c, the total p53 protein purified from human cells (Fig. 1), like the bacteria produced p53 protein, was strongly ubiquitinated (lane 2); however, the same amount of the acetylated p53 protein was barely ubiquitinated by Mdm2 under the same conditions (lane 4 versus lane 2). These results demonstrate directly that acetylation of p53 strongly inhibits its ubiquitination mediated by Mdm2.Figure 2Acetylation of p53 inhibits its ubiquitination by Mdm2 in vitro. a, colloidal blue staining of the purified components for in vitro ubiquitination assays. b, Western blot analysis of the in vitro ubiquitination reactions mediated by Mdm2 with the DO-1 monoclonal antibody. The purified bacteria-produced GST-p53 protein was incubated with different components as indicated.c, Western blot analysis of the in vitroubiquitination reactions on the purified acetylated p53 protein (lanes 3 and 4) or total p53 protein (lanes 1 and 2) with the DO-1 monoclonal antibody. The ubiquitination reactions were performed in the presence of Mdm2 (lanes 2 and 4) or in the absence of Mdm2 as controls (lanes 1 and 3).View Large Image Figure ViewerDownload Hi-res image Download (PPT)To further confirm the above findings, we searched for an acetylation-mimicking mutant for p53. Interestingly, it was previously reported that the histone H4 protein with the Lys → Gln mutation at the H4 acetylation site functionally behaved as the acetylated form to prevent Sir3p from binding H4 and spreading to form heterochromatin in yeast (26Hecht A. Laroche T. Strahl-Bolsinger S. Gasser S.M. Grunstein M. Cell. 1995; 80: 583-592Abstract Full Text PDF PubMed Scopus (692) Google Scholar). In fact, a Lys → Gln mutation can mimic the acetylated state of lysine (K) mainly because of the structure similarity between the Gln (Q) residue and the acetylated-lysine residue (Fig. 3 a). Thus, a p53(K-Q) mutant, in which all five acetylation sites (Lys-370, Lys-371, Lys-372, Lys-381, Lys-382, see Ref. 6Gu W. Roeder R.G. Cell. 1997; 90: 595-606Abstract Full Text Full Text PDF PubMed Scopus (2152) Google Scholar) were replaced by the glutamine residues, may mimic the acetylated form of p53. Interestingly, several studies have shown that the Lys → Arg mutation at the C-terminal acetylation sites only partially block Mdm2-mediated ubiquitination of the whole p53 polypeptide (18Honda R. Tanaka H. Yasuda H. FEBS Lett. 1997; 420: 25-27Crossref PubMed Scopus (1587) Google Scholar, 19Rodriguez M.S. Desterro J.M. Lain S. Lane D.P. Hay R.T. Mol. Cell. Biol. 2000; 20: 8458-8467Crossref PubMed Scopus (300) Google Scholar), indicating that there are additional lysine residues that can be ubiquitinated by Mdm2. Thus, the mechanism by which acetylation of p53 inhibits its ubiquitination by Mdm2 may contain two folds. First, acetylation of the p53 C-terminal domain blocks the ε-amino group of these acetylated lysine residues for ubiquitination, and second, acetylation of p53 may also induce protein conformation change to inhibit the ubiquitination of additional lysine residues that are not the acetylation targets. To test the above hypothesis, we examined whether the Lys → Gln mutation can effectively inhibit Mdm2-mediated ubiquitination of the whole p53 protein in vitro. Since the Lys → Arg mutation only eliminates the ε-amino group of these acetylation sites for ubiquitination without a neutralization of positive charges, we included a p53(K-R) mutant in the same assay as a comparison, in which the five acetylation sites were replaced by arginine residues (Fig. 3 b).Figure 3Regulation of Mdm2-mediated ubiquitination of p53 in vitro by the Lys → Gln mutation versusLys → Arg mutation on the acetylation sites. a, schematic representation of the similarities between the acetylated lysine residue and the glutamine residue. b, schematic representation of the p53(K-Q) mutant and p53(K-R) mutant. c, in vitro ubiquitination of the wild type p53 and p53 mutant proteins by Mdm2. The35S-labeled wild type p53 protein (lanes 1 and2) or p53(K-Q) mutant protein (lanes 3 and4) or p53(K-R) mutant protein (lanes 5 and6) were differentially ubiquitinated by Mdm2 in vitro (lanes 2, 4, and 6).View Large Image Figure ViewerDownload Hi-res image Download (PPT)For better quantitative analysis of the ubiquitination activities, we used the 35S-labeled, in vitro translated p53 proteins as substrates for the ubiquitination assay. Thus, similar reactions as described above (Fig. 2 b) were set up by incubating labeled p53 substrates, E1, E2 (GST-UbcH5c), E3 (GST-Mdm2), and ubiquitin. As shown in Fig. 3 c, the wild type p53 protein was strongly ubiquitinated by Mdm2 (lane 2 versus lane 1), whereas the p53(K-R) mutant protein had a significant, but only partial, reduction on Mdm2-mediated ubiquitination (∼60% decrease) (lane 6 versus lane 2), consistent with the previously published results (18Honda R. Tanaka H. Yasuda H. FEBS Lett. 1997; 420: 25-27Crossref PubMed Scopus (1587) Google Scholar, 19Rodriguez M.S. Desterro J.M. Lain S. Lane D.P. Hay R.T. Mol. Cell. Biol. 2000; 20: 8458-8467Crossref PubMed Scopus (300) Google Scholar). Strikingly, however, the Lys → Gln mutation on the same lysine residues induced a much stronger resistance to Mdm2-mediated ubiquitination, and the ubiquitination levels produced by the p53(K-Q) mutant protein were almost undetectable under the same conditions (lane 4). These results clearly demonstrate a much more effective inhibitory effect on Mdm2-mediated ubiquitination by the Lys → Gln mutation than the effect by the Lys → Arg mutation of these acetylation sites of p53. Based on the facts that the Lys → Gln mutation mimics the acetylated form of the lysine residue, whereas the Lys → Arg mutation only eliminates the ε-amino group of the acetylation sites for ubiquitination, our data further suggest that acetylation of p53, in addition to blocking the ubiquitination sites of these acetylated lysine residues, may also inhibit Mdm2-mediated ubiquitination of other lysine residues, possibly through inducing a protein conformational change.To examine the role of acetylation in the regulation of p53 ubiquitination in vivo, we tested the effect of acetylation on ubiquitination levels of endogenous p53 proteins. The acetylated p53 protein is much more easily obtained from the cells treated with the DNA damage reagents; however, to avoid other factors (e.g.p53 phosphorylation) that may also be involved in p53 stabilization under the DNA damage conditions (12Ito A. Lai C.H. Zhao X. Saito S. Hamilton M.H. Appella E. Yao T.P. EMBO J. 2001; 20: 1331-1340Crossref PubMed Scopus (436) Google Scholar), we chose to purify the acetylated form of endogenous p53 proteins from unstressed cells. As indicated in Fig. 4 a, high levels of ubiquitinated p53 proteins were present in the total p53 protein prepared from human Burkitt lymphoma cells (BL2) by immunoprecipitations with a p53 antibody against the full-length protein (lane 2). In contrast, the ubiquitinated p53 was almost undetectable in the acetylated form of the endogenous p53 protein (lane 1, Fig. 4 a), which was purified by immunoprecipitations with the antiacetylated p53-specific antibody from the same cells (see “Experimental Procedures”). Furthermore, we also examined the effect of acetylation on the half-life of p53in vivo. As indicated in Fig. 4 b, the half-life of the total p53 protein was less than 30 min. Strikingly, the acetylated form of p53, which constitutes only a very small portion of the total p53 protein in unstressed cells, appeared very stable; the half-life of the acetylated p53 was more than 2 h (Fig. 4 c). The above results demonstrate that acetylation of p53 can abrogate its ubiquitination and stabilize the p53 protein under physiological conditions.Figure 4The effect of acetylation on ubiquitination and stability of endogenous p53 in human cells (BL2). a, Western blot analysis of the ubiquitination levels of acetylated p53 and total p53 proteins immunoprecipitated from human BL2 cells. b, the half-life of the endogenous p53 protein (Total-p53). Cell extracts from human BL2 cells harvested at different time points as indicated after pretreated with cyclohexamide (CHX) were analyzed for p53 protein levels by Western blot with anti-p53 (DO-1). c, the half-life of the acetylated form of the endogenous p53 protein in BL2 cells. The acetylated p53 proteins were immunoprecipitated with the acetylated p53-specific antibody from the BL2 cell extracts harvested at different time points as indicated after pretreated with cyclohexamide (CHX) and further analyzed for p53 protein levels by Western blot with anti-p53 (DO-1).View Large Image Figure ViewerDownload Hi-res image Download (PPT)Thus, with several technical breakthroughs, we have demonstrated for the first time that acetylation of p53 directly inhibits ubiquitination-dependent proteolysis. More importantly, we have also provided further evidence elucidating a novel mechanism for acetylation-induced effects on p53 ubiquitination: acetylation of p53 not only blocks the ε-amino group of the acetylated lysine residues for ubiquitination, but also attenuates Mdm2-mediated ubiquitination of other unacetylated lysine residues, possibly through inducing a protein conformational change. Stabilization of p53 is critical for its effects on cell growth repression and apoptosis (1Appella E. Anderson C.W. Pathol. Biol. (Paris). 2000; 48: 227-245PubMed Google Scholar, 2Prives C. Manley J.L. Cell. 2001; 107: 815-818Abstract Full Text Full Text PDF PubMed Scopus (189) Google Scholar, 3Ashcroft M. Vousden K.H. Oncogene. 1999; 18: 7637-7643Crossref PubMed Scopus (369) Google Scholar, 4Pearson M. Carbone R. Sebastiani C. Cioce M. Fagioli M. Saito S. Higashimoto Y. Appella E. Minucci S. Pandolfi P.P. Pelicci P.G. Nature. 2000; 406: 207-210Crossref PubMed Scopus (1121) Google Scholar, 5Vogelstein B. Lane D. Levine A.J. Nature. 2000; 408: 307-310Crossref PubMed Scopus (5745) Google Scholar). Numerous studies imply the existence of multiple pathways involved in p53 stabilization in response to DNA damage or other types of stress (1Appella E. Anderson C.W. Pathol. Biol. (Paris). 2000; 48: 227-245PubMed Google Scholar, 2Prives C. Manley J.L. Cell. 2001; 107: 815-818Abstract Full Text Full Text PDF PubMed Scopus (189) Google Scholar, 3Ashcroft M. Vousden K.H. Oncogene. 1999; 18: 7637-7643Crossref PubMed Scopus (369) Google Scholar, 4Pearson M. Carbone R. Sebastiani C. Cioce M. Fagioli M. Saito S. Higashimoto Y. Appella E. Minucci S. Pandolfi P.P. Pelicci P.G. Nature. 2000; 406: 207-210Crossref PubMed Scopus (1121) Google Scholar, 5Vogelstein B. Lane D. Levine A.J. Nature. 2000; 408: 307-310Crossref PubMed Scopus (5745) Google Scholar, 25Li M. Chen D. Shiloh A. Luo J. Nikolaev A.Y. Qin J. Gu W. Nature. 2002; 416: 648-653Crossref PubMed Scopus (783) Google Scholar, 27Sherr C.J. Weber J.D. Curr. Opin. Genet. Dev. 2000; 10: 94-99Crossref PubMed Scopus (571) Google Scholar). It is generally thought that p53 is phosphorylated at multiple sites (mainly Ser-15 or Ser-20) and that these phosphorylation events promote p53 stabilization by preventing the binding with Mdm2 and rendering p53 more resistant to Mdm2-mediated degradation (28Shieh S.Y. Ikeda M. Taya Y. Prives C. Cell. 1997; 91: 325-334Abstract Full Text Full Text PDF PubMed Scopus (1728) Google Scholar, 29Maya R. Balass M. Kim S.T. Shkedy D. Leal J.F. Shifman O. Moas M. Buschmann T. Ronai Z. Shiloh Y. Kastan M.B. Katzir E. Oren M. Genes Dev. 2001; 15: 1067-1077Crossref PubMed Scopus (527) Google Scholar). Interestingly, however, several groups recently reported that mutations of these phosphorylation sites on p53 do not significantly inhibit the ability of DNA damage to stabilize p53 (30Ashcroft M. Kubbutat M.H. Vousden K.H. Mol. Cell. Biol. 1999; 19: 1751-1758Crossref PubMed Scopus (376) Google Scholar, 31Blattner C. Tobiasch E. Litfen M. Rahmsdorf H.J. Herrlich P. Oncogene. 1999; 18: 1723-1732Crossref PubMed Scopus (132) Google Scholar, 32Dumaz N. Meek D.W. EMBO J. 1999; 18: 7002-7010Crossref PubMed Scopus (390) Google Scholar, 33Ashcroft M. Taya Y. Vousden K.H. Mol. Cell. Biol. 2000; 20: 3224-3233Crossref PubMed Scopus (319) Google Scholar). Furthermore, some genotoxic drugs, such as actinomycin D, can stabilize p53 without provoking either Ser-15 or Ser-20 phosphorylation (33Ashcroft M. Taya Y. Vousden K.H. Mol. Cell. Biol. 2000; 20: 3224-3233Crossref PubMed Scopus (319) Google Scholar), raising the possibility that p53 can be stabilized without the modification of its N-terminal domain by phosphorylation. Our findings clearly support such notion by providing an alternative mechanism by which p53 can be stabilized through its acetylation.Acetylation, which modifies the lysine residue of target proteins including histone and non-histone proteins, is now recognized as an important regulatory step in transcriptional regulation (6Gu W. Roeder R.G. Cell. 1997; 90: 595-606Abstract Full Text Full Text PDF PubMed Scopus (2152) Google Scholar, 7Kouzarides T. EMBO J. 2000; 19: 1176-1179Crossref PubMed Scopus (998) Google Scholar, 8Sterner D.E. Berger S.L. Microbiol. Mol. Biol. Rev. 2000; 64: 435-459Crossref PubMed Scopus (1385) Google Scholar). A large number of the non-histone transcriptional factors have been demonstrated as bona fide substrates for acetyltransferases, suggesting that acetylation may represent another type of general protein modifications involved in functional regulation of transcriptional factors. Interestingly, both acetylation and ubiquitination modify the ε-amino group of the substrate lysine residues. Moreover, many of these identified acetylated substrates are involved in ubiquitination-dependent proteasome proteolysis, and several identified acetylation lysine residues are also potential ubiquitination sites (7Kouzarides T. EMBO J. 2000; 19: 1176

Phosphorylation Site Interdependence of Human P53 Post-Translational Modifications in Response to Stress.

Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation

Phosphorylation Of Ser312 Contributes To Tumor Suppression By P53 In Vivo

CDK9 Phosphorylates p53 on Serine Residues 33, 315 and 392

Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53.

Limited role of N-terminal phosphoserine residues in the activation of transcription by p53

Potentiality of DNA-dependent protein kinase to phosphorylate Ser46 of human p53

Regulation of p53 responses by post-translational modifications

Structural basis of how stress-induced MDMX phosphorylation activates p53

Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence.

Functional Analysis of the Acetylation of Human P53 in DNA Damage Responses

Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage.

Homeostatic Regulation of Base Excision Repair by A P53-Induced Phosphatase - Linking Stress Response Pathways with Dna Repair Proteins

Acetylation of P53 Inhibits Its Ubiquitination by Mdm2

Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53

P53 Regulation by Ubiquitin and Ubiquitin-Like Modifications

p53 modifications: exquisite decorations of the powerful guardian

p53: The Multifaceted Roles of Covalent Modifications in Cancer

Ser18 and 23 Phosphorylation is Required for P53-Dependent Apoptosis and Tumor Suppression

DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site

Post-translational modifications:the molecular basis for p53 regulation